Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361954278> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4361954278 abstract "<div>AbstractPurpose:<p>Monotherapy with eribulin or gemcitabine has been found to be moderately effective in treating soft-tissue sarcomas (STS). In this study, we evaluated the efficacy and safety of eribulin–gemcitabine combination therapy for the two most common histologic types of STS, liposarcoma and leiomyosarcoma.</p>Patients and Methods:<p>In this nonrandomized, multicenter, phase II study, we included patients with progressive disease who had received one or two courses of chemotherapy that included doxorubicin. Patients were administered 1.4 mg/m<sup>2</sup> eribulin and 1,000 mg/m<sup>2</sup> gemcitabine on days 1 and 8 every 3 weeks. The primary endpoint was progression-free survival rate at 12 weeks (PFSR<sub>12wks</sub>), with null and alternative hypotheses of PFSR<sub>12wks</sub> ≤20.0% and ≥40.0%, respectively. Exploratory biomarker analyses with next-generation sequencing (NGS) were performed on pretreatment tumor samples.</p>Results:<p>Among the 37 patients included, the overall PFSR<sub>12wks</sub> was 73.0%, achieving the primary endpoint. The objective response rate, disease control rate, median progression-free survival, and median overall survival were 16.2%, 78.4%, 5.6 months, and 31.9 months, respectively, without differences according to histologic type. New safety signals and treatment-related deaths were not documented. NGS-based transcriptome analysis revealed that functional enrichment in the TGFβ pathway was mostly associated with a poor outcome, whereas single genetic alterations largely failed to predict treatment outcome.</p>Conclusions:<p>Eribulin–gemcitabine combination therapy showed promising activity and an acceptable safety profile in patients with liposarcoma or leiomyosarcoma. Gene expression profiling with pathway enrichment analysis would have possibilities to have predictive value for survival outcome, necessitating further investigation to confirm.</p></div>" @default.
- W4361954278 created "2023-04-05" @default.
- W4361954278 creator A5002034433 @default.
- W4361954278 creator A5007208270 @default.
- W4361954278 creator A5007364197 @default.
- W4361954278 creator A5007992707 @default.
- W4361954278 creator A5024430163 @default.
- W4361954278 creator A5024676627 @default.
- W4361954278 creator A5026715008 @default.
- W4361954278 creator A5046647594 @default.
- W4361954278 creator A5049113012 @default.
- W4361954278 creator A5066288882 @default.
- W4361954278 creator A5067172804 @default.
- W4361954278 creator A5070060016 @default.
- W4361954278 creator A5076038022 @default.
- W4361954278 creator A5083550513 @default.
- W4361954278 creator A5085642896 @default.
- W4361954278 creator A5085790963 @default.
- W4361954278 date "2023-03-31" @default.
- W4361954278 modified "2023-09-26" @default.
- W4361954278 title "Data from Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma" @default.
- W4361954278 doi "https://doi.org/10.1158/1078-0432.c.6532644.v1" @default.
- W4361954278 hasPublicationYear "2023" @default.
- W4361954278 type Work @default.
- W4361954278 citedByCount "0" @default.
- W4361954278 crossrefType "posted-content" @default.
- W4361954278 hasAuthorship W4361954278A5002034433 @default.
- W4361954278 hasAuthorship W4361954278A5007208270 @default.
- W4361954278 hasAuthorship W4361954278A5007364197 @default.
- W4361954278 hasAuthorship W4361954278A5007992707 @default.
- W4361954278 hasAuthorship W4361954278A5024430163 @default.
- W4361954278 hasAuthorship W4361954278A5024676627 @default.
- W4361954278 hasAuthorship W4361954278A5026715008 @default.
- W4361954278 hasAuthorship W4361954278A5046647594 @default.
- W4361954278 hasAuthorship W4361954278A5049113012 @default.
- W4361954278 hasAuthorship W4361954278A5066288882 @default.
- W4361954278 hasAuthorship W4361954278A5067172804 @default.
- W4361954278 hasAuthorship W4361954278A5070060016 @default.
- W4361954278 hasAuthorship W4361954278A5076038022 @default.
- W4361954278 hasAuthorship W4361954278A5083550513 @default.
- W4361954278 hasAuthorship W4361954278A5085642896 @default.
- W4361954278 hasAuthorship W4361954278A5085790963 @default.
- W4361954278 hasConcept C121608353 @default.
- W4361954278 hasConcept C126322002 @default.
- W4361954278 hasConcept C141071460 @default.
- W4361954278 hasConcept C143998085 @default.
- W4361954278 hasConcept C203092338 @default.
- W4361954278 hasConcept C2775930923 @default.
- W4361954278 hasConcept C2776387010 @default.
- W4361954278 hasConcept C2776694085 @default.
- W4361954278 hasConcept C2780258809 @default.
- W4361954278 hasConcept C2780739268 @default.
- W4361954278 hasConcept C530470458 @default.
- W4361954278 hasConcept C535046627 @default.
- W4361954278 hasConcept C71924100 @default.
- W4361954278 hasConcept C90924648 @default.
- W4361954278 hasConceptScore W4361954278C121608353 @default.
- W4361954278 hasConceptScore W4361954278C126322002 @default.
- W4361954278 hasConceptScore W4361954278C141071460 @default.
- W4361954278 hasConceptScore W4361954278C143998085 @default.
- W4361954278 hasConceptScore W4361954278C203092338 @default.
- W4361954278 hasConceptScore W4361954278C2775930923 @default.
- W4361954278 hasConceptScore W4361954278C2776387010 @default.
- W4361954278 hasConceptScore W4361954278C2776694085 @default.
- W4361954278 hasConceptScore W4361954278C2780258809 @default.
- W4361954278 hasConceptScore W4361954278C2780739268 @default.
- W4361954278 hasConceptScore W4361954278C530470458 @default.
- W4361954278 hasConceptScore W4361954278C535046627 @default.
- W4361954278 hasConceptScore W4361954278C71924100 @default.
- W4361954278 hasConceptScore W4361954278C90924648 @default.
- W4361954278 hasLocation W43619542781 @default.
- W4361954278 hasOpenAccess W4361954278 @default.
- W4361954278 hasPrimaryLocation W43619542781 @default.
- W4361954278 hasRelatedWork W1608269846 @default.
- W4361954278 hasRelatedWork W1997961771 @default.
- W4361954278 hasRelatedWork W2183237771 @default.
- W4361954278 hasRelatedWork W2399717125 @default.
- W4361954278 hasRelatedWork W2622893994 @default.
- W4361954278 hasRelatedWork W2767929921 @default.
- W4361954278 hasRelatedWork W3168692696 @default.
- W4361954278 hasRelatedWork W4282918911 @default.
- W4361954278 hasRelatedWork W4361954278 @default.
- W4361954278 hasRelatedWork W4361967258 @default.
- W4361954278 isParatext "false" @default.
- W4361954278 isRetracted "false" @default.
- W4361954278 workType "article" @default.